Mr Lars Sorenson, CEO, Novo Nordisk (Photo Courtesy: Reuters)
However, the company has expressed interest in smaller licensing deals.
Mr Sorenson considers the insulin market to be big and growing fast that the company doesn't need to depend on acquisitions.
"Major acquisitions and major mergers are hugely distractive and often destructive," he told WSJ.
(News Source: The Wall Street Journal)